Xyphos

AbbVie in Campbell is a pharmaceutical company dedicated to discovering and developing innovative medicines for the future. Their mission is to improve the quality of life for individuals by providing effective healthcare solutions that enhance well-being. Generated from their website's infomation

Rigel is a clinical-stage drug development company that discovers and develops novel, small-molecule drugs for the treatment of inflammatory diseases, cancer and viral diseases. Its research focuses on intracellular signaling pathways and related targets that are critical to disease mechanisms. The company has collaborated with pharmaceutical partners to develop and market product candidates. Rigel has product development programs in inflammatory/autoimmune diseases, such as rheumatoid arthritis, thrombocytopenia, asthma and allergy, as well as in cancer. Its lead product candidate, R788, completed Phase I clinical trials for the treatment of rheumatoid arthritis, in 2005.

Agios Pharmaceuticals Inc, based in San Mateo, CA, is a pioneering leader in the field of cellular metabolism, dedicated to developing innovative therapies for patients with rare diseases such as pyruvate kinase deficiency, thalassemia, and sickle cell disease. By prioritizing patient needs and fostering collaborative relationships with healthcare professionals and patient communities, Agios aims to create impactful, disease-modifying therapies that address unmet medical needs. Founded on the principles of scientific excellence and community engagement, Agios cultivates a supportive and flexible work environment that empowers its employees to contribute their best. This commitment to culture and collaboration drives the company's ongoing success in advancing groundbreaking treatments for those affected by rare diseases. Generated from the website